CIGB-814, an altered peptide ligand derived from human heat-shock protein 60, decreases anti-cyclic citrullinated peptides antibodies in patients with rheumatoid arthritis
- 29 Downloads
Rheumatoid arthritis (RA) is a chronic T cell-mediated autoimmune disease. Serum autoantibodies against cyclic citrullinated peptides (anti-CCP) are significant markers for diagnosis and prognosis of this disease. Induction of immune tolerance as therapeutic approach for RA constitutes a current research focal point. In this sense, we carried out a phase I clinical trial in RA patients with a new therapeutic candidate (called CIGB-814); which induced mechanisms associated with restoration of peripheral tolerance in preclinical studies. CIGB 814 is an altered peptide ligand (APL), derived from a CD4+ T cell epitope of human heat-shock protein 60 (HSP60), an autoantigen involved in the pathogenesis of RA. Twenty patients with moderate disease activity were included in this open label trial. Sequential dose-escalation of 1, 2.5 and 5 mg of CIGB-814 was studied. Consecutive groups of six, five, and nine patients received a subcutaneous dose weekly of the peptide during the first month and one dose monthly during the next 5 months. The peptide was well tolerated and reduced disease activity. Here, we reported the quantification of anti-CCP antibodies during the treatment with this APL and in the follow-up stage. Anti-CCP antibodies were quantified in the plasma from patients by a commercial enzyme immunoassay at baseline (T0) and at weeks 28 and 48. Results showed that CIGB-814 induced a significant reduction of anti-CCP antibodies. In addition, this decrease correlated with clinical improvement in patients assessed by Disease Activity Score in 28 joints (DAS28) criteria. These findings reinforce the therapeutic potential of CIGB-814.
KeywordsAnti-CCP APL CIGB-814 HSP60 Rheumatoid arthritis
We thank the patients who participated in this study.
Study sponsorship was provided by CIGB and Ministry of Public Health of Cuba.
Compliance with ethical standards
The Ethics and Scientifics Committees at each study site approved the protocol: National Reference Center for Rheumatic Disease, Center for Genetic Engineering and Biotechnology, and Cuban Regulatory Authority (reference number 05-017-12-B).
All subjects provided theirs written informed consent. Patients were recruited from the National Reference Center for Rheumatic Diseases, Havana. This clinical trial was registered under number RPCEC00000238 at the Cuban Registry of Clinical Trials (www.registroclinico.sld.cu).
- 5.Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37CrossRefGoogle Scholar
- 7.Bacquet-Deschryver H, Jouen F, Quillard M, Ménard JF, Goëb V, Lequerré T, Mejjad O, Daragon A, Tron F, le Loët X, Vittecoq O (2008) Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol 28:445–455CrossRefGoogle Scholar
- 8.Genovese MC, Kaine JL, Lowenstein MB, Giudice JD, Baldassare A, Schechtman J, Fudman E, Kohen M, Gujrathi S, Trapp RG, Sweiss NJ, Spaniolo G, Dummer W, ACTION Study Group (2008) Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized,blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 58:2652–2661CrossRefGoogle Scholar
- 15.Barberá A, Lorenzo N, van Kooten P, van Roon J, de Jager W, Prada D, Gómez J, Padrón G, van Eden W, Broere F, del Carmen Domínguez M (2016) APL1, an altered peptide ligand derived from human heat-shock protein 60, increases the frequency of Tregs and its suppressive capacity against antigen responding effector CD4+T cells from rheumatoid arthritis patients. Cell Stress Chaperones 21:735–744CrossRefGoogle Scholar
- 17.Cabrales-Rico A, Ramos Y, Besada V, del Carmen Domínguez M, Lorenzo N, García O, Alexis J, Prada D, Reyes Y, López AM, Masforrol Y, Garay H, González LJ (2017) Development and validation of a bioanalytical method based on LC–MS/MS analysis for the quantitation of CIGB-814 peptide in plasma from rheumatoid arthritis patients. J Pharm Biomed Anal 143:130–140CrossRefGoogle Scholar
- 18.Prada D, Gómez J, Lorenzo N et al (2018) Phase I clinical trial with a novel altered peptide ligand derived from human heat-shock protein 60 for treatment of rheumatoid arthritis: safety, pharmacokinetics and preliminary therapeutic effects. J Clin Trials 8:339. https://doi.org/10.4172/2167-0870.1000339 CrossRefGoogle Scholar
- 19.Schneider M, Kruger K (2013) Rheumatoid arthritis –early diagnosis and disease management. Deutsches Arzteblatt Int 110(27–28):477–484Google Scholar
- 25.Montesinos MC, Takedachi M, Thompson LF (2007) The anti-inflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5′-nucleotidase: findings in a study of ecto-5′-nucleotidase gene-deficient mice. Arthritis Rheum 56:1440–1445CrossRefGoogle Scholar